Obesity Canada: Generic Semaglutide Approval Should Reshape Coverage

Obesity Canada is calling on governments, insurers and employers to revisit how obesity treatment is covered following Health Canada's authorization of two generic semaglutide injections, with Scientific Director Dr. Sanjeev Sockalingam writing that lower-cost approved options may help reduce one of the most persistent barriers in obesity care [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Two G7-First Approvals in Five Weeks

Health Canada authorized the first generic semaglutide injection on April 28, 2026, filed by Dr. Reddy's Laboratories as a generic version of brand-name Ozempic, making Canada the first G7 country to approve a generic of the molecule [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. On May 1, 2026, Health Canada authorized a second generic semaglutide injection, this one filed by Canadian-based Apotex, again referencing brand-name Ozempic [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

According to the May 1 notice, Health Canada is currently reviewing seven other submissions for generic semaglutide from different companies, with more regulatory decisions expected in the coming weeks and months [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. Both authorized generics are indicated for the once-weekly treatment of adult patients with type 2 diabetes to manage blood sugar levels [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

The Access Gap Obesity Canada Highlights

In commentary published by Obesity Canada, Dr. Sockalingam wrote that fewer than 20 per cent of Canadians with private drug benefit plans have access to Health Canada-approved obesity treatment medications [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. He argued that affordability should not depend on whether someone can find a lower-cost product, and that the approval of generic semaglutide raises a larger question about whether people living with obesity can access evidence-based care when it is clinically appropriate [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Obesity Canada noted that estimates show untreated obesity cost Canada $27.6 billion in 2023, including direct healthcare costs and broader productivity losses [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. The organization said it does not endorse specific medications, brands, or manufacturers, and that its focus is on ensuring access to comprehensive, evidence-based care, including Health Canada-approved medications when clinically appropriate [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

What the Regulator Said About Generic Quality

Health Canada described the generic versions of semaglutide as complex synthetic products that are pharmaceutically equivalent to the brand name biologic drug, and said its review ensures that differences between these products do not affect the safety, efficacy, or quality of the drug [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. The regulator added that the availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the healthcare system [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

Dr. Sockalingam echoed that framing, writing that Health Canada-approved generic medications are regulated and reviewed for safety, effectiveness, and quality, and that this review process gives patients, healthcare professionals, pharmacists, payers, and policymakers a common foundation for decision-making [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Coverage Decisions Now Sit With Plans

Obesity Canada wrote that as the first G7 country to approve generic semaglutide, Canada now has an opportunity to connect regulatory progress with meaningful access to care, and that coverage decisions should reflect the science of obesity as a chronic disease [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/]. The organization stated that people living with obesity should not have to pay out of pocket for evidence-based treatment for a chronic disease when similar treatment pathways are covered for other chronic conditions [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Readers can follow application progress on our generic semaglutide tracker, check plan-specific questions through the insurance coverage checker, or review additional context on Wegovy, Mounjaro, Zepbound and Rybelsus on our drug pages, or in our FAQ.

This article is for informational purposes only and does not constitute medical advice.